The Programme for Global Health and Vaccination Research (GLOBVAC) is extended for the period 2012-2020. The overall aim of the Programme is to support research that can contribute to sustainable improvements in health and health equity for poor people in low- and middle-income countries (LMIC).
The deadline for submitting a poster has been extended to 31 May 2012.
Approximately NOK 160 million is available for this call, while the applicants’ grant request totaled NOK 553.3 million.
The U.S. Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, and Grand Challenges Canada invite global problem solvers to answer their second call for innovative solutions to dramatically reduce maternal and newborn deaths and stillbirths.
Norad gir muligheter for støtte til lovende mobilbaserte løsninger for kvinners og barns helse i utviklingsland.
A total of 125 project outlines were received by the application deadline of 30. November 2011.
Thirty years after AIDS was first described, there is still no effective vaccine against the virus. Researchers are working to find out whether a HIV vaccine developed by a Norwegian biotech company can be administered nasally.
Global health research is characterized as one of the country’s “particularly strong research areas” in the recent evaluation of biology, medicine and health research in Norway.
A new call has been launched under the Programme for Global Health and Vaccination Research – GLOBVAC. 3-5 year projects are invited in all thematic areas of the Programme. Project outlines, which are mandatory, must be submitted by 30. November 2011, and full proposals by 18. April 2012. It is expected that 15-20 projects will be funded. A total of approximately NOK 160 mill. (USD 30 mill.) is available for this call.